Over a year ago, I participated in my first plant medicine ceremonies, and it’s finally time to talk about it. This might be the hardest article I’ve written to date, but if it even just helps just one person it will be worth it.
We are undeniably in the middle of a psychedelic renaissance. Research is emerging rapidly. MDMA-assisted psychotherapy for PTSD is in Phase 3 clinical trials, with the FDA granting Breakthrough Therapy status treatment will likely be rolled out by 2023.
MAPS is pioneering much of the work, top-notch universities like UCL, John Hopkins, and NYU are opening Psychedelic research centers. Psychedelic startups and investment funds are popping up across the US. In late January, the first psychedelic ETF hit the stock markets and blew up in value by 10x within its first weeks of trading.